DSAM Partners London Ltd purchased a new position in Urogen Pharma (NASDAQ:URGN) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 74,500 shares of the company’s stock, valued at approximately $2,348,000. DSAM Partners London Ltd owned about 0.57% of Urogen Pharma at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Alps Advisors Inc. purchased a new position in shares of Urogen Pharma in the second quarter worth $195,000. Shikiar Asset Management Inc. purchased a new position in shares of Urogen Pharma in the third quarter worth $665,000. LLBH Private Wealth Management LLC purchased a new position in shares of Urogen Pharma in the second quarter worth $695,000. Spark Investment Management LLC purchased a new position in shares of Urogen Pharma in the second quarter worth $856,000. Finally, Bainco International Investors purchased a new position in shares of Urogen Pharma in the third quarter worth $2,284,000. 36.41% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.watchlistnews.com/dsam-partners-london-ltd-invests-2-35-million-in-urogen-pharma-urgn/1675872.html.

A number of research analysts have issued reports on the stock. Zacks Investment Research raised shares of Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Wednesday, August 2nd. Oppenheimer Holdings, Inc. set a $32.00 price target on shares of Urogen Pharma and gave the stock a “buy” rating in a report on Monday, August 14th. Finally, Jefferies Group LLC raised their target price on shares of Urogen Pharma from $27.00 to $37.00 and gave the stock a “buy” rating in a report on Monday, October 9th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $28.50.

Urogen Pharma Profile

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Institutional Ownership by Quarter for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.